Combination chemotherapy of small cell carcinoma of the lung

M. D. Abeloff, David S Ettinger, A. Inalsingh, T. A. Hazra

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

From September 1973 to October 1974, 34 patients with small cell carcinoma of the lung were treated with monthly courses of BCVP: BCNU 60 mg/M2 i.v., cyclophosphamide 800 mg/M2 i.v., and vincristine 1.5 mg/M2 i.v. on day 1 and procarbazine 100 mgm/M2 p.o./day from day 1-10. Six patients had limited disease and 28 had extensive disease. Twenty four patients had prior radiotherapy to the primary tumor. The objective response rate to BCVP in evaluable patients with measurable disease was 18/31 (58%) with 3 complete (CR) and 15 partial responses (PR). The response to BCVP in patients who had received no prior radiotherapy was 7/10 with 3 CR. Leukopenia was the major toxicity. WBC count was less than 1500 in 11 cases. Mean WCB nadir was 2200. There were no drug related deaths. Mean duration of response is +108 days (53 to 218 days). 6/18 responders remain in remission. Patients with limited disease have a mean survival of +196 days from start of BCVP; those with extensive disease have a mean survival of +132 days. The responders and nonresponders have similar mean survivals (+138 and +131 days) but 9/18 responders are alive while only 1/13 nonresponders survives. This combination of cytotoxic drugs has a significant objective response rate in small cell carcinoma of the lung and merits further evaluation in the overall management of this neoplasm.

Original languageEnglish (US)
Title of host publicationProceedings of the American Association for Cancer Research
Volume16
Edition66
StatePublished - 1975

Fingerprint

Small Cell Lung Carcinoma
Combination Drug Therapy
Survival
Radiotherapy
Procarbazine
Carmustine
Leukopenia
Vincristine
Drug Combinations
Cyclophosphamide
Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Abeloff, M. D., Ettinger, D. S., Inalsingh, A., & Hazra, T. A. (1975). Combination chemotherapy of small cell carcinoma of the lung. In Proceedings of the American Association for Cancer Research (66 ed., Vol. 16)

Combination chemotherapy of small cell carcinoma of the lung. / Abeloff, M. D.; Ettinger, David S; Inalsingh, A.; Hazra, T. A.

Proceedings of the American Association for Cancer Research. Vol. 16 66. ed. 1975.

Research output: Chapter in Book/Report/Conference proceedingChapter

Abeloff, MD, Ettinger, DS, Inalsingh, A & Hazra, TA 1975, Combination chemotherapy of small cell carcinoma of the lung. in Proceedings of the American Association for Cancer Research. 66 edn, vol. 16.
Abeloff MD, Ettinger DS, Inalsingh A, Hazra TA. Combination chemotherapy of small cell carcinoma of the lung. In Proceedings of the American Association for Cancer Research. 66 ed. Vol. 16. 1975
Abeloff, M. D. ; Ettinger, David S ; Inalsingh, A. ; Hazra, T. A. / Combination chemotherapy of small cell carcinoma of the lung. Proceedings of the American Association for Cancer Research. Vol. 16 66. ed. 1975.
@inbook{70911225e68f41e0803db44ebcb7e80d,
title = "Combination chemotherapy of small cell carcinoma of the lung",
abstract = "From September 1973 to October 1974, 34 patients with small cell carcinoma of the lung were treated with monthly courses of BCVP: BCNU 60 mg/M2 i.v., cyclophosphamide 800 mg/M2 i.v., and vincristine 1.5 mg/M2 i.v. on day 1 and procarbazine 100 mgm/M2 p.o./day from day 1-10. Six patients had limited disease and 28 had extensive disease. Twenty four patients had prior radiotherapy to the primary tumor. The objective response rate to BCVP in evaluable patients with measurable disease was 18/31 (58{\%}) with 3 complete (CR) and 15 partial responses (PR). The response to BCVP in patients who had received no prior radiotherapy was 7/10 with 3 CR. Leukopenia was the major toxicity. WBC count was less than 1500 in 11 cases. Mean WCB nadir was 2200. There were no drug related deaths. Mean duration of response is +108 days (53 to 218 days). 6/18 responders remain in remission. Patients with limited disease have a mean survival of +196 days from start of BCVP; those with extensive disease have a mean survival of +132 days. The responders and nonresponders have similar mean survivals (+138 and +131 days) but 9/18 responders are alive while only 1/13 nonresponders survives. This combination of cytotoxic drugs has a significant objective response rate in small cell carcinoma of the lung and merits further evaluation in the overall management of this neoplasm.",
author = "Abeloff, {M. D.} and Ettinger, {David S} and A. Inalsingh and Hazra, {T. A.}",
year = "1975",
language = "English (US)",
volume = "16",
booktitle = "Proceedings of the American Association for Cancer Research",
edition = "66",

}

TY - CHAP

T1 - Combination chemotherapy of small cell carcinoma of the lung

AU - Abeloff, M. D.

AU - Ettinger, David S

AU - Inalsingh, A.

AU - Hazra, T. A.

PY - 1975

Y1 - 1975

N2 - From September 1973 to October 1974, 34 patients with small cell carcinoma of the lung were treated with monthly courses of BCVP: BCNU 60 mg/M2 i.v., cyclophosphamide 800 mg/M2 i.v., and vincristine 1.5 mg/M2 i.v. on day 1 and procarbazine 100 mgm/M2 p.o./day from day 1-10. Six patients had limited disease and 28 had extensive disease. Twenty four patients had prior radiotherapy to the primary tumor. The objective response rate to BCVP in evaluable patients with measurable disease was 18/31 (58%) with 3 complete (CR) and 15 partial responses (PR). The response to BCVP in patients who had received no prior radiotherapy was 7/10 with 3 CR. Leukopenia was the major toxicity. WBC count was less than 1500 in 11 cases. Mean WCB nadir was 2200. There were no drug related deaths. Mean duration of response is +108 days (53 to 218 days). 6/18 responders remain in remission. Patients with limited disease have a mean survival of +196 days from start of BCVP; those with extensive disease have a mean survival of +132 days. The responders and nonresponders have similar mean survivals (+138 and +131 days) but 9/18 responders are alive while only 1/13 nonresponders survives. This combination of cytotoxic drugs has a significant objective response rate in small cell carcinoma of the lung and merits further evaluation in the overall management of this neoplasm.

AB - From September 1973 to October 1974, 34 patients with small cell carcinoma of the lung were treated with monthly courses of BCVP: BCNU 60 mg/M2 i.v., cyclophosphamide 800 mg/M2 i.v., and vincristine 1.5 mg/M2 i.v. on day 1 and procarbazine 100 mgm/M2 p.o./day from day 1-10. Six patients had limited disease and 28 had extensive disease. Twenty four patients had prior radiotherapy to the primary tumor. The objective response rate to BCVP in evaluable patients with measurable disease was 18/31 (58%) with 3 complete (CR) and 15 partial responses (PR). The response to BCVP in patients who had received no prior radiotherapy was 7/10 with 3 CR. Leukopenia was the major toxicity. WBC count was less than 1500 in 11 cases. Mean WCB nadir was 2200. There were no drug related deaths. Mean duration of response is +108 days (53 to 218 days). 6/18 responders remain in remission. Patients with limited disease have a mean survival of +196 days from start of BCVP; those with extensive disease have a mean survival of +132 days. The responders and nonresponders have similar mean survivals (+138 and +131 days) but 9/18 responders are alive while only 1/13 nonresponders survives. This combination of cytotoxic drugs has a significant objective response rate in small cell carcinoma of the lung and merits further evaluation in the overall management of this neoplasm.

UR - http://www.scopus.com/inward/record.url?scp=0016738146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016738146&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0016738146

VL - 16

BT - Proceedings of the American Association for Cancer Research

ER -